Cerity Partners’s Praxis Precision Medicines PRAX Stock Holding History

Cerity Partners’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$388K	Sell	1,159 -440	-28%	-$139K	﹤0.01%	2603
2026 Q1	$515K	Sell	1,599 -2,328	-59%	-$720K	﹤0.01%	2268
2025 Q4	$1.16M	Sell	3,927 -1,523	-28%	-$284K	﹤0.01%	1640
2025 Q3	$289K	Sell	5,450 -161	-3%	-$7.81K	﹤0.01%	2302
2025 Q2	$236K	Buy	+5,611	New	+$214K	﹤0.01%	2269
2025 Q1	–	Sell	-4,364	Closed	-$334K	–	2593
2024 Q4	$334K	Sell	4,364 -24	-0.5%	-$1.74K	﹤0.01%	1982
2024 Q3	$252K	Buy	+4,388	New	+$237K	﹤0.01%	2183
2024 Q2	–	Sell	-4,261	Closed	-$260K	–	2371
2024 Q1	$260K	Buy	+4,261	New	+$191K	﹤0.01%	1950

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Cerity Partners's PRAX Position: Q2 2026 in Review

Cerity Partners reduced its Praxis Precision Medicines (PRAX) stake by 28% in Q2 2026, selling an estimated $139K and leaving 1,159 shares worth $388K. The position accounts for ﹤0.01% of the portfolio, ranked #2603.

Cerity Partners first reported a position in PRAX in Q1 2024 and has held it in 8 quarters since. The position peaked at $1.16M in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Cerity Partners held 1,159 shares of Praxis Precision Medicines worth $388K as of Q2 2026.
Cerity Partners sold 440 Praxis Precision Medicines shares in Q2 2026, an estimated $139K.
Praxis Precision Medicines made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2603 holding.
Cerity Partners first reported a position in Praxis Precision Medicines in Q1 2024 and has held it in 8 quarters since.
Cerity Partners's Praxis Precision Medicines position peaked at $1.16M in Q4 2025.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.